Emerald Health Pharmaceuticals (“EHP”), is a private, clinical-stage biotechnology company developing a new class of proprietary molecules with unique capabilities that can potentially modify and reverse disease progression in patients suffering from devastating neurodegenerative, inflammatory, autoimmune and fibrotic diseases with notable unmet needs and no cures. EHP is currently developing its two lead product candidates for the treatment of multiple sclerosis, Parkinson’s disease, and the orphan diseases systemic sclerosis (a severe form of scleroderma) and Huntington’s disease, which all involve increasingly debilitating and painful symptoms and are life-threatening. In preclinical studies, EHP has demonstrated the safety and tolerability of its lead product, EHP-101, in a large placebo-controlled Phase 1 study and has begun enrollment for its Phase 2 for the treatment of systemic sclerosis, with initial Phase 2 results expected in Q321.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):